Uitkomsten PHILEMON-onderzoek

Bronnen:

1. Jerkeman J, Winther Eskelund C, Hutchings M, et al. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haemat. 2018;5;3:109-16